Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis

Table 3

Effects of roxithromycin on SGRQ scores in NCFB.

Parameters	Group	Baseline	6 months	value; 6 months versus baseline	value; versus control at baseline	value; versus control at 6 months
Total score	Control			0.326
	Roxithromycin			0.013	0.367	0.021
Symptom	Control			0.145
	Roxithromycin			0.016	0.276	0.035
Activity	Control			0.293
	Roxithromycin			0.072	0.473	0.237
Impact	Control			0.702
	Roxithromycin			0.224	0.406	0.324

compared with 6 months of controls.